174 related articles for article (PubMed ID: 1552500)
101. Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum.
Pettit GR; Singh SB; Schmidt JM; Niven ML; Hamel E; Lin CM
J Nat Prod; 1988; 51(3):517-27. PubMed ID: 3404149
[TBL] [Abstract][Full Text] [Related]
102. Synthesis and cellular pharmacology studies of a series of 2-amino-3-aroyl-4-substituted thiophene derivatives.
Romagnoli R; Baraldi PG; Pavani MG; Cruz-Lopez O; Hamel E; Balzarini J; Brognara E; Zuccato C; Gambari R
Med Chem; 2010 Nov; 6(6):329-43. PubMed ID: 21054275
[TBL] [Abstract][Full Text] [Related]
103. Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues.
Nam NH; Kim Y; You YJ; Hong DH; Kim HM; Ahn BZ
Bioorg Med Chem Lett; 2002 Aug; 12(15):1955-8. PubMed ID: 12113817
[TBL] [Abstract][Full Text] [Related]
104. Antitubulin effects of derivatives of 3-demethylthiocolchicine, methylthio ethers of natural colchicinoids, and thioketones derived from thiocolchicine. Comparison with colchicinoids.
Muzaffar A; Brossi A; Lin CM; Hamel E
J Med Chem; 1990 Feb; 33(2):567-71. PubMed ID: 2299625
[TBL] [Abstract][Full Text] [Related]
105. Antitumor agents. 199. Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis.
Zhang SX; Feng J; Kuo SC; Brossi A; Hamel E; Tropsha A; Lee KH
J Med Chem; 2000 Jan; 43(2):167-76. PubMed ID: 10649972
[TBL] [Abstract][Full Text] [Related]
106. Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
Li L; Wang HK; Kuo SC; Wu TS; Lednicer D; Lin CM; Hamel E; Lee KH
J Med Chem; 1994 Apr; 37(8):1126-35. PubMed ID: 8164254
[TBL] [Abstract][Full Text] [Related]
107. Synthesis of biologically active polyphenolic glycosides (combretastatin and resveratrol series).
Orsini F; Pelizzoni F; Bellini B; Miglierini G
Carbohydr Res; 1997 Jun; 301(3-4):95-109. PubMed ID: 9232838
[TBL] [Abstract][Full Text] [Related]
108. Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization.
Herdman CA; Strecker TE; Tanpure RP; Chen Z; Winters A; Gerberich J; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
Medchemcomm; 2016 Dec; 7(12):2418-2427. PubMed ID: 28217276
[TBL] [Abstract][Full Text] [Related]
109. Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity.
Hatanaka T; Fujita K; Ohsumi K; Nakagawa R; Fukuda Y; Nihei Y; Suga Y; Akiyama Y; Tsuji T
Bioorg Med Chem Lett; 1998 Dec; 8(23):3371-4. PubMed ID: 9873736
[TBL] [Abstract][Full Text] [Related]
110. Combretastatin-based compounds with therapeutic characteristics: a patent review.
Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A
Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715
[No Abstract] [Full Text] [Related]
111. Discovery, synthesis, activities, structure-activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive review.
Singh SB
Nat Prod Rep; 2024 Feb; 41(2):298-322. PubMed ID: 38009216
[TBL] [Abstract][Full Text] [Related]
112. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum.
Pettit GR; Singh SB; Niven ML; Hamel E; Schmidt JM
J Nat Prod; 1987; 50(1):119-31. PubMed ID: 3598594
[TBL] [Abstract][Full Text] [Related]
113. Two new polymorphic forms of combretastatin A-4, an antitumour agent.
Grześkiewicz AM; Stefański T; Dutkiewicz Z; Buśko D; Kubicki M
Acta Crystallogr C Struct Chem; 2020 Oct; 76(Pt 10):958-964. PubMed ID: 33016266
[TBL] [Abstract][Full Text] [Related]
114. Structure-activity relationship of 1-propargyl-5-halopyrimidin-2-ones. Metaphase arresting properties and competitive inhibition of colchicine binding to tubulin.
Dornish JM; Oftebro R
Invest New Drugs; 1983; 1(3):203-11. PubMed ID: 6678868
[TBL] [Abstract][Full Text] [Related]
115. Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors.
Kumar S; Mehndiratta S; Nepali K; Gupta MK; Koul S; Sharma PR; Saxena AK; Dhar KL
Org Med Chem Lett; 2013 Mar; 3(1):3. PubMed ID: 23452433
[TBL] [Abstract][Full Text] [Related]
116. Pharmaceutical design of antimitotic agents based on combretastatins.
Hsieh HP; Liou JP; Mahindroo N
Curr Pharm Des; 2005; 11(13):1655-77. PubMed ID: 15892667
[TBL] [Abstract][Full Text] [Related]
117. Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones.
Xia Y; Yang ZY; Hour MJ; Kuo SC; Xia P; Bastow KF; Nakanishi Y; Namrpoothiri P; Hackl T; Hamel E; Lee HK
Bioorg Med Chem Lett; 2001 May; 11(9):1193-6. PubMed ID: 11354375
[TBL] [Abstract][Full Text] [Related]
118. Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]triazolo[4,3-
Xu Q; Wang Y; Xu J; Sun M; Tian H; Zuo D; Guan Q; Bao K; Wu Y; Zhang W
ACS Med Chem Lett; 2016 Dec; 7(12):1202-1206. PubMed ID: 27994764
[TBL] [Abstract][Full Text] [Related]
119. Drug-Clinical Agent Molecular Hybrid: Synthesis of Diaryl(trifluoromethyl)pyrazoles as Tubulin Targeting Anticancer Agents.
Hura N; Naaz A; Prassanawar SS; Guchhait SK; Panda D
ACS Omega; 2018 Feb; 3(2):1955-1969. PubMed ID: 30023819
[TBL] [Abstract][Full Text] [Related]
120. Leishmanicidal activity of combretastatin analogues and heteroanalogues.
del Rey B; Ramos AC; Caballero E; Inchaustti A; Yaluff G; Medarde M; Rojas de Arias A; San Feliciano A
Bioorg Med Chem Lett; 1999 Sep; 9(18):2711-4. PubMed ID: 10509921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
